

PTO/SB/96 (01-08)
Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)

Applicant/Patent Owner: Morten Meldal et al.

Application No./Patent No.: 09/787,881 Filed/Issue Date: March 23, 2001

Entitled: PEG-BASED MACROMONOMERS, CHEMICALLY INERT POLYMERS PREPARED THEREFROM AND THE USE OF THESE POLYMERS FOR ORGANIC SYNTHESIS AND ENZYME REACTIONS

Novo Nordisk A/S, a corporation
(Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of less than the entire right, title and interest
(The extent (by percentage) of its ownership interest is _____ %)

in the patent application/patent identified above by virtue of either:

A. ☐ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

OR

B. ☒ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:

1. From: Morten Meldal et al. To: Carlsberg A/S
The document was recorded in the United States Patent and Trademark Office at
Reel 011945, Frame 0925, or for which a copy thereof is attached.
2. From: Carlsberg A/S To: Versamatrix A/S
The document was recorded in the United States Patent and Trademark Office at
Reel 019224, Frame 0062, or for which a copy thereof is attached.
3. From: Versamatrix A/S To: Novo Nordisk A/S
The document was recorded in the United States Patent and Trademark Office at
Reel 020897, Frame 0066, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

☐ As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.


[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

<u>/Wesley A. Nicolas, Registration No. 56,129/</u>	<u>January 27, 2010</u>
Signature	Date
<u>Wesley A. Nicolas, Registration No. 56,129</u>	<u>(609) 987-5800</u>
Printed or Typed Name	Telephone Number
<u>IP Counsel</u>	
Title	

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



**POWER OF ATTORNEY,
REVOCATION OF PREVIOUSLY GRANTED POWER OF ATTORNEY, AND
AUTHORIZATION TO MAKE SUBMISSIONS REGARDING OWNERSHIP**

Power of Attorney:

Novo Nordisk A/S (hereinafter "Novo Nordisk"), hereby appoints and acknowledges its appointment of the attorneys of the Novo Nordisk Inc. Intellectual Property Department (the latter including the attorneys and agents associated with U.S. Patent and Trademark Office Customer Number 23650) and any successor entities or appointed agents thereof (hereinafter "NNI Attorneys") to act for Novo Nordisk in all proceedings before the U.S. Patent and Trademark Office ("USPTO").

Such proceedings shall include, without limitation, filing, prosecution, withdrawal, maintenance, and abandonment of such U.S. patent applications (and International (PCT) Patent Applications filed with the USPTO), as well as the initiation and handling of appeal, reexamination, reissue, interference, cancellation, correction, or similar proceedings involving U.S. patents and patent applications and the transaction of all other business associated with such patent applications and patents in the U.S. Patent and Trademark Office. By virtue of this appointment, Novo Nordisk authorizes the NNI Attorneys to receive all communications, official actions, and decisions, of the U.S. Patent and Trademark Office and to lodge and withdraw any legal measures deemed fit by the NNI Attorneys with respect to such patents and patent applications.

Revocation of Previously Granted Power of Attorney:

Immediately upon the filing of this document with USPTO in connection with any patent or patent application, all previously granted powers of attorney in connection with the patent or patent application will be revoked.

Authorization To Make Submissions Regarding Ownership:

Novo Nordisk further hereby authorizes and empowers the NNI attorneys to make any appropriate submissions regarding Novo Nordisk's ownership interest in any such patent applications or patents on behalf of Novo Nordisk A/S with the USPTO in accordance with 37 C.F.R. § 3.73(b) (or any substantially similar successor thereof) and having the application number(s) listed thereon.

The individual whose signature and title is supplied below is authorized to grant this power of attorney and authorization to the NNI Attorneys on behalf of Novo Nordisk.


Lars Kellberg

Vice President – Corporate Patents